Codexis Inc
Open
SectorHealthcare
1.41 -1.4
Overview
Share price change
24h
Min
1.3900000000000001
Max
1.44
Income | -3.3M -12M |
|---|---|
Sales | -333K 15M |
EPS | -0.13 |
Profit margin | -80.489 |
Employees | 146 |
EBITDA | -4.3M -11M |
Next Earnings | 5 Nov 2026 |
|---|
Market Cap | -1.5M 160M |
|---|---|
Previous open | 2.81 |
Previous close | 1.41 |
News Sentiment
By Acuity
50%
50%
144 / 339 Healthcare
Codexis Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Codexis Inc Forecast
Sentiment
By Acuity
144 / 339 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.